SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.

Biotech Giants: SG&A Expense Trends from 2014-2023

__timestampAgios Pharmaceuticals, Inc.Blueprint Medicines Corporation
Wednesday, January 1, 2014191200007890000
Thursday, January 1, 20153599200014456000
Friday, January 1, 20165071400019218000
Sunday, January 1, 20177112400027986000
Monday, January 1, 201811414500047928000
Tuesday, January 1, 201913203400096388000
Wednesday, January 1, 2020149070000157743000
Friday, January 1, 2021121445000195293000
Saturday, January 1, 2022121673000237374000
Sunday, January 1, 2023119903000295141000
Monday, January 1, 2024156784000359272000
Loading chart...

Unlocking the unknown

SG&A Efficiency: A Tale of Two Biotechs

In the competitive world of biotechnology, managing operational expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Blueprint Medicines has seen a staggering increase in SG&A expenses, growing nearly 3,700% from 2014 to 2023. In contrast, Agios Pharmaceuticals experienced a more modest increase of approximately 525%.

Blueprint's expenses surged particularly from 2020 onwards, reflecting its aggressive expansion and investment in commercial operations. Meanwhile, Agios maintained a steadier growth trajectory, indicating a more conservative approach. This divergence highlights different strategic priorities: Blueprint's focus on rapid growth versus Agios's emphasis on sustainable scaling. Understanding these trends offers valuable insights into how these companies navigate the financial demands of the biotech industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025